Omeros is a a commercial-stage biopharmaceutical company focused on discovering, developing and ccommercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The company's drug product OMIDRIA? is marketed in the U.S. for use during cataract surgery or intraocular lens replacement. In its pipeline the company has clinical-stage development programs focused on: complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.
  • TickerOMER
  • ISINUS6821431029
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Liana Moussatos ...
  • Shveta Dighe

Q1 Financials; Consistent OMIDRIA Sales but Burning Cash Quickly

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

Liana Moussatos ...
  • Shveta Dighe

Q1 Financials; Consistent OMIDRIA Sales but Burning Cash Quickly

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ResearchPool Subscriptions

Get the most out of your insights

Get in touch